A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
András Nagy(University of Szeged), Zhaoyang Li(Guiyang Medical University), Kimberly Duff(Takeda (United States)), Alexander Bauer(Takeda (Austria)), Fred Okonneh(Takeda (United States)), Juan Carlos Rondón(Clinical Pharmacology of Miami), Leman Yel(Children's Hospital of Philadelphia)
Cited by 3
Related Papers
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4